Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)
Retrieved on:
Wednesday, August 11, 2021
ALS, Hospital, Radical (chemistry), Amyotrophic lateral sclerosis, Dihydroxy-E,Z,E-PUFA, Speech, Health, Medulla oblongata, Walking, Safety, FA, Caregiver, Patient, Retrotope, Physician, Neurodegeneration, PSP, Lipid peroxidation, Technology, Hannover Medical School, Membrane, Massachusetts General Hospital, Death, Cognition, INAD, Tissue, HIV disease progression rates, LOS, Clinical trial, Brain, Behavior, Government budget balance, RT001, Massachusetts, LA, LPO, Research, Oxidative stress, Cell, Degenerative disease, AMD, Department of Neurology, Xuanwu hospital, History, FDA, Disease, GLOBE, Infantile neuroaxonal dystrophy, Mitochondrial membrane transport protein, Neurology, DHA, Pharmaceutical industry
PSP is a progressive, neurodegenerative disorder that dramatically impacts the health and lives of not only patients, but also their families and other caregivers.
Key Points:
- PSP is a progressive, neurodegenerative disorder that dramatically impacts the health and lives of not only patients, but also their families and other caregivers.
- Study participants have been randomized to receive either RT001 or placebo daily for 48 weeks.
- The primary endpoint of the trial is change from baseline in the PSP Rating Scale (PSPRS) at 48 weeks.
- The study also includes several secondary and exploratory endpoints intended to further elucidate the efficacy and safety profile of RT001 as compared to placebo.